Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05961982 · ClinicalTrials.gov registry record · NA
Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study
A NA study of Pancreatic Neoplasm, sponsored by Ohio State University Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 84
- Enrollment target
- 1
- Study location
NCT05961982 is a NA study of Pancreatic Neoplasm that is actively recruiting participants, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 84 participants, below the 652-participant average among 10 other Pancreatic Neoplasm trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05961982, a NA study of Pancreatic Neoplasm, is actively recruiting participants, sponsored by Ohio State University Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 84 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial evaluates the safety and effectiveness of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for the management of patients with pancreatic tumors (including cysts) performed during recommended surveillance endoscopic ultrasound examinations. Pancreatic tumors (cysts) can progress to pancreatic cancer at rate of more than 25% per year risk. Pancreatic cancer is a fatal disease that is difficult to diagnose at an early stage, and the five-year survival rate is currently less than 10%. It is projected to be the second leading cause of cancer-related mortality by the year 2030. A procedure known as radiofrequency ablation may help. Radiofrequency ablation is an established way to treat benign and cancerous tumors in the human body. In the last 5 years, radiofrequency ablation has been applied to treat precancerous tumors (including cysts) in the pancreas. This procedure implements a medical technology that destroys tumors in a much less invasive way compared to traditional surgical removal. By delivering a high-frequency alternating current, radiofrequency ablation uses electrical energy and heat to destroy cancer cells. Radiofrequency ablation is being recognized as a management option in patients with high-risk pancreatic tumors (cysts) but are not deemed surgical candidates. While surgical removal offers a chance of cure, pancreatic surgeries have 20-40% morbidity rate (short and long-term complication) and a 1-2% mortality rate in patients who are surgical candidates. Furthermore, radiofrequency ablation can potentially decrease the need for frequent imaging/surveillance of the pancreatic tumor (cyst). In patients with immediate prohibitive, but reversible risks for surgery, radiofrequency ablation of a high-risk tumors (cysts) can potentially prevent further progression of the lesion and bridge the time before the need for surgical resection.
Conditions Studied
Interventions
- PROCEDURE Computed Tomography
- OTHER Electronic Health Record Review
- PROCEDURE Chemical Ablation
- PROCEDURE Endoscopic Ultrasound-Guided Fine-Needle Aspiration
- PROCEDURE Endoscopic Ultrasound-Guided Radiofrequency Ablation
Study Locations (1)
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2023-04-24 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05961982
The ClinicalTrials.gov registry entry for NCT05961982 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 652-participant average among 10 other Pancreatic Neoplasm trials with a reported enrollment target (87% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Computed Tomography is the first listed.
NCT05961982 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05961982 about?
NCT05961982 is a clinical study titled "Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study". This clinical trial evaluates the safety and effectiveness of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) for the management of patients with pancreatic tumors (including cysts) performed during recommended surveillance endoscopic ultrasound examinations. Pancreatic tumors (cysts)...
What is the current status of trial NCT05961982?
This trial is currently recruiting. It is a NA study. The enrollment target is 84 participants. The study started on 2023-04-24. Estimated completion is 2028-12-31.
What conditions does trial NCT05961982 study?
This clinical trial studies the following conditions: Pancreatic Neoplasm.
What interventions are being tested in trial NCT05961982?
The interventions under investigation include: Computed Tomography (PROCEDURE), Electronic Health Record Review (OTHER), Chemical Ablation (PROCEDURE), Endoscopic Ultrasound-Guided Fine-Needle Aspiration (PROCEDURE), Endoscopic Ultrasound-Guided Radiofrequency Ablation (PROCEDURE).
Who is sponsoring clinical trial NCT05961982?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05961982 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
RECRUITING · Phase 3
-
Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
RECRUITING · Early Phase 1
-
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
RECRUITING · Phase 1
-
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
RECRUITING · Phase 1
-
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.